EMPA-REG OUTCOME: Analysis in Women with T2DM and CVD

Slideshow

A recent trial found that empagliflozin can reduce the risk of cardiovascular deaths in type 2 diabetes patients; are results similar in men and women?

   

Related Videos
Related Content

Empagliflozin (Jardiance) Receives CKD Approval from US FDA

September 22nd 2023

Pulmonary Embolism 101 with Parth Rali, MD

September 5th 2023

USPSTF Updates Guidance on Screening for Hypertensive Disorders of Pregnancy

September 19th 2023

Don't Miss a Beat: ESC Heart Failure Association Preview

May 19th 2023

Expert Perspective: FDA CRDAC Vote on Patisiran for ATTR-CM, with Ahmad Masri, MD, MS

September 16th 2023

Discussing Advances in Structural Heart Disease, with Elliot Elias, MD, MPH

September 15th 2023

Empagliflozin (Jardiance) Receives CKD Approval from US FDA

September 22nd 2023

Pulmonary Embolism 101 with Parth Rali, MD

September 5th 2023

USPSTF Updates Guidance on Screening for Hypertensive Disorders of Pregnancy

September 19th 2023

Don't Miss a Beat: ESC Heart Failure Association Preview

May 19th 2023

Expert Perspective: FDA CRDAC Vote on Patisiran for ATTR-CM, with Ahmad Masri, MD, MS

September 16th 2023

Discussing Advances in Structural Heart Disease, with Elliot Elias, MD, MPH

September 15th 2023

Empagliflozin (Jardiance) Receives CKD Approval from US FDA

September 22nd 2023

Pulmonary Embolism 101 with Parth Rali, MD

September 5th 2023

USPSTF Updates Guidance on Screening for Hypertensive Disorders of Pregnancy

September 19th 2023

Don't Miss a Beat: ESC Heart Failure Association Preview

May 19th 2023

Expert Perspective: FDA CRDAC Vote on Patisiran for ATTR-CM, with Ahmad Masri, MD, MS

September 16th 2023

Discussing Advances in Structural Heart Disease, with Elliot Elias, MD, MPH

September 15th 2023
© 2023 MJH Life Sciences

All rights reserved.